Kangchen Pharmaceutical is a private company.

Kangchen Pharmaceutical refers to Guangzhou Kangchen Pharmaceutical Co., Ltd., which was registered and established in 1997. The legal representative is Gao Haien. Its address is No. 71 Dongpeng Avenue, East District, Economic and Technological Development Zone, Luogang District, Guangzhou. A modern pharmaceutical company mainly engaged in the research, development, production and marketing of modern medical imaging contrast agents. In 2013, it was listed on the main board of the Hong Kong Stock Exchange. Its subsidiaries include Kangchen Pharmaceutical (Inner Mongolia) Co., Ltd., Kangchen Pharmaceutical (Hall Guosi) Co., Ltd., Guangxi Yulin Pharmaceutical Group Co., Ltd., etc., mainly operate well-known brands such as Kangchen and Yulin, and currently have business in more than 30 countries and regions.

The development history of Kangchen Pharmaceutical

1. In 1997, Kangchen Pharmaceutical was officially born.

2. In 1998, Urduqing Granules and Gadopentetate dimeglumine Injection were fully launched into the national market.

3. In 2000, Urduqing Granules were included in the national second-level protected traditional Chinese medicine varieties, and Gadopentetate dimeglumine injection was included in the National Medical Insurance List.

4. In 2002, Guangzhou Kangchen Industrial Park was completed.

5. In 2003, Guangzhou Kangchen Pharmaceutical passed GMP certification.

6. In 2004, Guangzhou Kangchen Pharmaceutical Co., Ltd. was established and gradually established a marketing network covering 31 provinces, municipalities, and autonomous regions. While consolidating and developing the domestic market, it is also actively exploring the international market, and its products It has been sold to Hong Kong, Macao, Taiwan, Southeast Asia, the United States, Japan, Canada and other countries and regions.

7. In 2005, the overall business scale exceeded 100 million yuan.

8. In 2006, Kangchen Kidney Drug Research Center was established.

9. In 2008, Guangdong Kangchen Pharmaceutical Group was established and chose to cooperate with Lenovo Hony Capital to officially start the listing process.

10. In 2009, Inner Mongolia Kangyuan Pharmaceutical Co., Ltd. was acquired.

11. In 2010, Kangchen Pharmaceutical Group won the title of “Pioneer in Innovation and Development of the Pharmaceutical Industry in Guangdong Province”.

12. In 2012, the "Kangchen" brand won the title of Guangdong Province Famous Trademark.

13. In 2013, Kangchen Pharmaceutical Group was listed on the main board of the Hong Kong Stock Exchange.

14. In 2014, Guangzhou Kangchen was approved as "Kidney Disease Drug Engineering Technology Research Center".

15. In 2015, it was approved to establish a postdoctoral research station.

16. In 2016, the evidence-based medical research results of Niduqing Granules were officially released.

17. In 2017, Yulin Pharmaceutical started its A-share main board listing and spent 1 billion yuan to start construction of a new park.

18. In 2018, the new drug Tangshen was approved to carry out clinical research.

19. In 2019, Kangchen Pharmaceutical Group ranked among the top 100 pharmaceutical companies in China in 2018.

20. In 2023, Kangchen Pharmaceutical Group ranked 22nd in the 2022 list of TOP100 Chinese traditional medicine companies.

Summary

Kangchen Pharmaceutical takes the mission of inheriting the past, developing the new, and benefiting the people with good medicine, and has formed the core values ??of humanism, sincerity, responsibility, and enjoyment, and is committed to creating The flagship of nephrology, becoming a leading and outstanding pharmaceutical company in multiple specialties.